Back to Search Start Over

36-month clinical outcomes of patients with venous thromboembolism:GARFIELD-VTE

Authors :
Turpie, Alexander G.G.
Farjat, Alfredo E.
Haas, Sylvia
Ageno, Walter
Weitz, Jeffrey I.
Goldhaber, Samuel Z.
Goto, Shinya
Angchaisuksiri, Pantep
Kayani, Gloria
Lopes, Renato D.
Chiang, Chern En
Gibbs, Harry
Verhamme, Peter
ten Cate, Hugo
Muntaner, Juan
Schellong, Sebastian
Bounameaux, Henri
Prandoni, Paolo
Kakkar, Ajay K.
Loualidi, Ab
Colak, Abdurrahim
Bezuidenhout, Abraham
Abdool-Carrim, Abu
Azeddine, Addala
Beyers, Adriaan
Dees, Adriaan
Mohamed, Ahmed
Aksoy, Ahmet
Abiko, Akihiko
Watanabe, Akinori
Krichell, Alan
Fernandez, Alberto Alfredo
Tosetto, Alberto
Khotuntsov, Alexey
Oropallo, Alisha
Slocombe, Alison
Kelly, Allan
Clark, Amanda
Gad, Amr
Arouni, Amy
Schmidt, Andor
Berni, Andrea
Kleiban, Andres Javier
Machowski, Andrew
Kazakov, Andrey
Galvez, Angel
Lockman, Ann
Boomars, Karin
Zhang, Lei
Bax, W. A.
Turpie, Alexander G.G.
Farjat, Alfredo E.
Haas, Sylvia
Ageno, Walter
Weitz, Jeffrey I.
Goldhaber, Samuel Z.
Goto, Shinya
Angchaisuksiri, Pantep
Kayani, Gloria
Lopes, Renato D.
Chiang, Chern En
Gibbs, Harry
Verhamme, Peter
ten Cate, Hugo
Muntaner, Juan
Schellong, Sebastian
Bounameaux, Henri
Prandoni, Paolo
Kakkar, Ajay K.
Loualidi, Ab
Colak, Abdurrahim
Bezuidenhout, Abraham
Abdool-Carrim, Abu
Azeddine, Addala
Beyers, Adriaan
Dees, Adriaan
Mohamed, Ahmed
Aksoy, Ahmet
Abiko, Akihiko
Watanabe, Akinori
Krichell, Alan
Fernandez, Alberto Alfredo
Tosetto, Alberto
Khotuntsov, Alexey
Oropallo, Alisha
Slocombe, Alison
Kelly, Allan
Clark, Amanda
Gad, Amr
Arouni, Amy
Schmidt, Andor
Berni, Andrea
Kleiban, Andres Javier
Machowski, Andrew
Kazakov, Andrey
Galvez, Angel
Lockman, Ann
Boomars, Karin
Zhang, Lei
Bax, W. A.
Source :
GARFIELD-VTE investigators , Turpie , A G G , Farjat , A E , Haas , S , Ageno , W , Weitz , J I , Goldhaber , S Z , Goto , S , Angchaisuksiri , P , Kayani , G , Lopes , R D , Chiang , C E , Gibbs , H , Verhamme , P , ten Cate , H , Muntaner , J , Schellong , S , Bounameaux , H , Prandoni , P , Kakkar , A K , Loualidi , A , Colak , A , Bezuidenhout , A , Abdool-Carrim , A , Azeddine , A , Beyers , A , Dees , A , Mohamed , A , Aksoy , A , Abiko , A , Watanabe , A , Krichell , A , Fernandez , A A , Tosetto , A , Khotuntsov , A , Oropallo , A , Slocombe , A , Kelly , A , Clark , A , Gad , A , Arouni , A , Schmidt , A , Berni , A , Kleiban , A J , Machowski , A , Kazakov , A , Galvez , A , Lockman , A , Boomars , K , Zhang , L & Bax , W A 2023 , ' 36-month clinical outcomes of patients with venous thromboembolism : GARFIELD-VTE ' , Thrombosis Research , vol. 222 , pp. 31-39 .
Publication Year :
2023

Abstract

Background: Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality worldwide. Methods: GARFIELD-VTE is a prospective, non-interventional observational study of real-world treatment practices. We aimed to capture the 36-month clinical outcomes of 10,679 patients with objectively confirmed VTE enrolled between May 2014 and January 2017 from 415 sites in 28 countries. Findings: A total of 6582 (61.6 %) patients had DVT alone, 4097 (38.4 %) had PE ± DVT. At baseline, 98.1 % of patients received anticoagulation (AC) with or without other modalities of therapy. The proportion of patients on AC therapy decreased over time: 87.6 % at 3 months, 73.0 % at 6 months, 54.2 % at 12 months and 42.0 % at 36 months. At 12-months follow-up, the incidences (95 % confidence interval [CI]) of all-cause mortality, recurrent VTE and major bleeding were 6.5 (7.0–8.1), 5.4 (4.9–5.9) and 2.7 (2.4–3.0) per 100 person-years, respectively. At 36-months, these decreased to 4.4 (4.2–4.7), 3.5 (3.2–2.7) and 1.4 (1.3–1.6) per 100 person-years, respectively. Over 36-months, the rate of all-cause mortality and major bleeds were highest in patients treated with parenteral therapy (PAR) versus oral anti-coagulants (OAC) and no OAC, and the rate of recurrent VTE was highest in patients on no OAC versus those on PAR and OAC. The most frequent cause of death after 36-month follow-up was cancer (n = 565, 48.6 %), followed by cardiac (n = 94, 8.1 %), and VTE (n = 38, 3.2 %). Most recurrent VTE events were DVT alone (n = 564, 63.3 %), with the remainder PE, (n = 236, 27.3 %), or PE in combination with DVT (n = 63, 7.3 %). Interpretation: GARFIELD-VTE provides a global perspective of anticoagulation patterns and highlights the accumulation of events within the first 12 months after diagnosis. These findings may help identify treatment gaps for subsequent interventions to improve patient outcomes in this patient p

Details

Database :
OAIster
Journal :
GARFIELD-VTE investigators , Turpie , A G G , Farjat , A E , Haas , S , Ageno , W , Weitz , J I , Goldhaber , S Z , Goto , S , Angchaisuksiri , P , Kayani , G , Lopes , R D , Chiang , C E , Gibbs , H , Verhamme , P , ten Cate , H , Muntaner , J , Schellong , S , Bounameaux , H , Prandoni , P , Kakkar , A K , Loualidi , A , Colak , A , Bezuidenhout , A , Abdool-Carrim , A , Azeddine , A , Beyers , A , Dees , A , Mohamed , A , Aksoy , A , Abiko , A , Watanabe , A , Krichell , A , Fernandez , A A , Tosetto , A , Khotuntsov , A , Oropallo , A , Slocombe , A , Kelly , A , Clark , A , Gad , A , Arouni , A , Schmidt , A , Berni , A , Kleiban , A J , Machowski , A , Kazakov , A , Galvez , A , Lockman , A , Boomars , K , Zhang , L & Bax , W A 2023 , ' 36-month clinical outcomes of patients with venous thromboembolism : GARFIELD-VTE ' , Thrombosis Research , vol. 222 , pp. 31-39 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1383761010
Document Type :
Electronic Resource